- 产品
- 详情
- 推荐
收藏
¥面议
1mg起订
产品规格
可售数量: 1mg
iFluor 555酰肼
货号 | 1083 | 存储条件 | f/l |
规格 | 1 mg | ||
Ex (nm) | 556 | Em (nm) | 569 |
分子量 | 839.83 | 溶剂 | Water |
产品详细介绍 |
简要概述
产品基本信息
货号:1083
产品名称:iFluor 555酰肼
规格:1mg
储存条件:-15℃避光防潮
保质期:12个月
产品物理化学光谱特性
分子量:839.83
溶剂:DMSO
激发波长(nm):552
发射波长(nm):567
产品介绍
iFluor 555酰肼是美国AAT Bioquest生产的iFluor系列荧光染料。AAT Bioquest的iFluor 染料经过优化,可用于标记蛋白质,特别是抗体。这些染料是明亮的,光稳定的并且对蛋白质具有 小的猝灭。荧光仪器的主要激光线(例如,350,405,488,555和633nm)可以很好地激发它们。 iFluor 555染料的荧光激发和发射 值分别为~550nm和~570nm。 iFluor 555系列的光谱特性基本上与Cy3®相同(Cy3®是GE Healthcare的商标)。与Cy3探针相比,iFluor 555家族具有更强的荧光和更高的光稳定性。它们的荧光与pH值无关,pH值为3至11.这些光谱特性使这种新型染料系列成为Cy3®的优良替代品。 iFluor 555系列已成为Cy3®和AlexaFluor®555标记染料(Cy3®和AlexaFluor®是Invitrogen和GE Health Care的商标)的替代品。 iFluor 555酰肼相当稳定,与羰基(如醛)具有良好的反应性和选择性。百萤生物是AAT Bioquest的中国代理商,为您提供优质的iFluor 555酰肼。
参考文献
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer
Authors: O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J.
Journal: Cancer Chemother Pharmacol (2007): 79
Mutational Patterns Associated with the 69 Insertion Complex in Multi-drug-resistant HIV-1 Reverse Transcriptase that Confer Increased Excision Activity and High-level Resistance to Zidovudine
Authors: Cases-Gonzalez CE, Franco S, Martinez MA, Menendez-Arias L.
Journal: J Mol Biol (2007): 298
A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab
Authors: Nakajima H, Mizuta N, Mizuta M, Nakatsukasa K, Kobayashi A, Hachimine Y, Sakaguchi K, Fujiwara I, Sawai K.
Journal: Gan To Kagaku Ryoho (2006): 1305
A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis
Authors: Zhu LZ, Fu Y, Chu NH, Ye ZZ, Xiao HP, Wang W, Yuan SL, Zhang X, Luo YA, Ma LP.
Journal: Zhonghua Jie He He Hu Xi Za Zhi (2006): 520
Activity-guided isolation of scopoletin and isoscopoletin, the inhibitory active principles towards CCRF-CEM leukaemia cells and multi-drug resistant CEM/ADR5000 cells, from Artemisia argyi
Authors: Adams M, Efferth T, Bauer R.
Journal: Planta Med (2006): 862
Advances in the study of drugs for the treatment of multi-drug resistant tuberculosis
Authors: Tang SJ.
Journal: Zhonghua Jie He He Hu Xi Za Zhi (2006): 567
Assessment of resistance in multi drug resistant tuberculosis patients
Authors: Irfan S, Hassan Q, Hasan R.
Journal: J Pak Med Assoc (2006): 397
Bacteriologic profile of bacteremia due to multi-drug resistant bacteria at Charles-Nicolle Hospital of Tunis
Authors: Saidani M, Boutiba I, Ghozzi R, Kammoun A, Ben Redjeb S.
Journal: Med Mal Infect (2006): 163
Clinical Prediction Tool to Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multi-Drug Resistance
Authors: Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, Graffunder E, McNutt LA.
Journal: Antimicrob Agents Chemother. (2006)
Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection
Authors: Biancofiore G, Tascini C, Bisa M, Gemignani G, Bindi ML, Leonildi A, Giannotti G, Menichetti F.
Journal: Minerva Anestesiol. (2006)
-
18502920169
-
029-68064558
AAT Bioquest iFluor 555酰肼 货号1083
¥面议
¥面议
1mg可售
询价单发送成功~